The value of [18f]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma

Clinical Lymphoma and Myeloma

Volumn 8, Issue 2, 2008, Pages 94-99

  Karantanis, Dimitrios ^a   Subramaniam, Rathan M ^a   Peller, Patrick J ^a   Lowe, Val J ^a   Durski, Jolanta M ^a   Collins, Douglas A ^a   Georgiou, Evangelos ^b   Ansell, Stephen M ^a   Wiseman, Gregory A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

FDG uptake; Nasal lesions; Neck nodes; Paranasal lesions

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL VIABILITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NOSE CAVITY; NOSE DISEASE; PARANASAL SINUS; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; T CELL LYMPHOMA; TIME SERIES ANALYSIS; TUMOR BIOPSY;

EID: 44649171004     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.010     Document Type: Article

References (25)

1. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Exttanodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20:103-11.
2. Arber DA, Weiss LM, Albujar PF, et al. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993; 17:392-9.
3. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100:366-75.
4. Chan JK. Natural killer cell neoplasms. Anat Pathol 1998; 3:77-145.
5. de Bruin PC, Jiwa M, Oudejans JJ, et al. Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood 1994; 83:1612-8.
6. Chan JK, Yip TT, Tsang WY, et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994; 18:938-46.
7. Chiang AK, Chan AC, Srivastava G, et al. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer 1997; 73:332-8.
8. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and telationship with the International Prognostic Index. Blood 2004; 103:216-21.
9. Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6-11.
10. Nakamura S, Suchi T Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995; 19:284-96.
11. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24:181-9.
12. Aviles A, Diaz NR, Neri N, et al. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22:215-20.
13. Lei KI, Suen JJ, Hui P, et al. Primary nasal and nasopharyngeal lymphomas: a comparative study of clinical presentation and treatment outcome. Clin Oncol (R Coll Radiol) 1999; 11:379-87.
14. Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after tadiation treatment. J Clin Oncol 2000; 18:54-63.
15. Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factots, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54:182-90.
16. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
17. Schodet H, Meta J, Yap C, et al. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42:1139-43.
18. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positton emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 6:603-9.
19. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicatot in the tteatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma 2000; 39:543-53.
20. Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055-63.
21. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91:850-4.
22. Jacobs SA, Vidnovic N, Joyce J, et al. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005; 11:7146s-50s.
23. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-27.
24. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16:1514-23.
25. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkins lymphoma. J Clin Oncol 2005; 23:4643-51.